Gillian McGovern, Associate Editor

Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.

Iptocopan demonstrated superiority when treating patients with immunoglobulin A nephropathy and is the first drug to specifically target the alternative complement pathway.

The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.

This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.

The AAN speaker highlights what health care providers need to know when treating migraines in populations on hormone therapy, as well as how hormones can influence migraines.

PAPs in this model can significantly reduce OOP costs regardless of the pharmacy setting.

Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.

With this approval, alectinib is the first anaplastic lymphoma kinase inhibitor to be approved for patients with ALK-positive, early-stage non-small cell lung cancer.

In a trial that compared gepotidacin to ceftriaxone plus azithromycin in patients with urogenital gonorrhea, gepotidacin presented a 92.6% microbiological success rate.

Speaker Monica Diaz describes the detrimental impact climate change has on the transmission and increases in infectious disease cases.

The product is currently being investigated alongside TLX101 in the IPAX-Linz and IPAX-2 clinical trials, and have previously shown efficacy in the IPAX-1 trial.

The study is the first of 5 studies co-published by AYR Wellness and LECOM and showcases improvements in physical, social, and mental well-being with minimal AEs.

The extension trial of atogepant demonstrated an 8.5-day improvement of monthly migraine days at weeks 13 through 16 and no new safety signals were observed.

The authors note that additional research needs to be conducted to confirm whether the findings are consistent in adult patients.

Although the vaccine has not yet been tested in humans, it demonstrated 100% efficacy in protecting primates who were injected with human Marburg virus disease.

Pandemic-related growing pains were common within health care, bringing unique challenges for health systems.

In this NCCN session, James M. Foran, MD, described the different FLT3 inhibitors that are available for FLT3-mutated AML, as well as considerations for the future.

In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma.

In addition to oral administration, patients with partial-onset seizures can now take the antiseizure medication via a nasogastric tube if the tablet is crushed and mixed with water.

The antibody drug conjugate was used in combination with the anti-cancer drug SG3249, and demonstrated efficacy in mouse models after 1 week.

Benralizumab was previously approved by the FDA in 2017 as an add-on maintenance therapy for patients 12 years and older.

The results demonstrated similar overall survival between patients with chronic lymphocytic leukemia who discontinued specialized follow-ups versus those who continued.

The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.

Venetoclax, which is approved for leukemia, blocks a function of the BCL-2 protein and has previously shown efficacy in a small proportion of patients with multiple myeloma.

Piezo1 is a protein produced by type 2 innate lymphoid cells when activated by an allergen and can limit the immune cell’s activity when triggered by a reaction.

The treatment is indicated for adolescents at least 12 years of age who weigh at least 25 kg without a previous treatment history of antiretroviral therapies.

Despite the positive results demonstrated in a prior phase 2 trial, AMX0035 failed to meet the phase 3 trial’s primary end point in treating patients with amyotrophic lateral sclerosis.

A study about modifiable risk factors on a “weak spot” in the brain network found that diabetes, pollution, and alcohol were most likely to contribute to dementia disorders.

The decision follows phase 3 trial results that demonstrated improved progression-free survival and confirmed the safety of Dato-DXd in patients with breast cancer.